Drug Profile


Alternative Names: 7 OMEN; Menogarol; NSC 269148; Tomosar; TUT 7; U 52047; UT 7

Latest Information Update: 04 Jul 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Taiho Pharmaceutical
  • Class Anthracyclines; Cytostatic antibiotics; Nogalamucins
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Breast cancer; Cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Malignant melanoma; Multiple myeloma; Myeloid leukaemia; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
  • Discontinued Lymphoma

Most Recent Events

  • 04 Jul 2006 No development reported - Phase-I for Cancer in Canada (unspecified route)
  • 04 Jul 2006 No development reported - Phase-II for Breast cancer in European Union (unspecified route)
  • 04 Jul 2006 No development reported - Phase-II for Cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top